Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.

Fiorucci, S; Cipriani, S; Mencarelli, A; Baldelli, F; Bifulco, G; Zampella, A

Fiorucci, S; Cipriani, S; Mencarelli, A; Baldelli, F; Bifulco, G; Zampella, A.

Affiliation

Fiorucci S; University of Perugia, Dipartimento di Medicina Clinica e Sperimentale, Nuova Facoltà di Medicina e Chirurgia, Via Gerardo Dottori n° 1 S. Andrea delle Fratte, 06132 Perugia, Italy. Fiorucci@unipg.it

Mini Rev Med Chem ; 11(9): 753-62, 2011 Aug.

Article in En | MEDLINE | ID: mdl-21707532

Subject(s)

Chenodeoxycholic Acid/analogs & derivatives; Liver Diseases/drug therapy; Metabolic Diseases/drug therapy; Receptors, Cytoplasmic and Nuclear/agonists; Animals; Chenodeoxycholic Acid/chemistry; Chenodeoxycholic Acid/pharmacokinetics; Chenodeoxycholic Acid/therapeutic use; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Hypoglycemic Agents/chemistry; Hypoglycemic Agents/pharmacokinetics; Hypoglycemic Agents/therapeutic use; Receptors, Cytoplasmic and Nuclear/metabolism

Search on Google

Add to My VHL

XML

PubMed Links

Database: MEDLINE Main subject: Chenodeoxycholic Acid / Receptors, Cytoplasmic and Nuclear / Liver Diseases / Metabolic Diseases Type of study: Prognostic_studies Language: En Journal: Mini Rev Med Chem Year: 2011 Type: Article Affiliation country: Italy

Search on Google

Add to My VHL

XML

PubMed Links